KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) FCF Margin: 2017-2025

Historic FCF Margin for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -100.60%.

  • Aquestive Therapeutics' FCF Margin fell 1228.00% to -100.60% in Q3 2025 from the same period last year, while for Sep 2025 it was 387.23%, marking a year-over-year increase of 44559.00%. This contributed to the annual value of -3,563.29% for FY2024, which is 354871.00% down from last year.
  • Latest data reveals that Aquestive Therapeutics reported FCF Margin of -100.60% as of Q3 2025, which was down 25.46% from -80.19% recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year FCF Margin high stood at 79.16% for Q1 2023, and its period low was -269.90% during Q1 2025.
  • For the 3-year period, Aquestive Therapeutics' FCF Margin averaged around -62.67%, with its median value being -65.95% (2023).
  • Its FCF Margin has fluctuated over the past 5 years, first spiked by 192,430bps in 2021, then plummeted by 18,350bps in 2025.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' FCF Margin stood at -77.58% in 2021, then skyrocketed by 15,612bps to 78.54% in 2022, then plummeted by 11,609bps to -37.54% in 2023, then surged by 5,210bps to 14.55% in 2024, then slumped by 1,228bps to -100.60% in 2025.
  • Its FCF Margin was -100.60% in Q3 2025, compared to -80.19% in Q2 2025 and -269.90% in Q1 2025.